William Blair Has Positive Forecast for TRDA FY2024 Earnings

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Research analysts at William Blair upped their FY2024 earnings estimates for Entrada Therapeutics in a report released on Tuesday, November 5th. William Blair analyst M. Minter now forecasts that the company will earn $1.19 per share for the year, up from their prior estimate of $0.43. The consensus estimate for Entrada Therapeutics’ current full-year earnings is $0.98 per share. William Blair also issued estimates for Entrada Therapeutics’ Q4 2024 earnings at ($0.69) EPS, Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.69) EPS and FY2025 earnings at ($2.95) EPS.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, topping the consensus estimate of $0.65 by $0.90. The company had revenue of $94.69 million during the quarter, compared to analyst estimates of $55.00 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%.

Other equities analysts also recently issued reports about the stock. HC Wainwright lifted their target price on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday. Oppenheimer lifted their price target on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday.

Entrada Therapeutics Trading Up 3.1 %

NASDAQ:TRDA opened at $19.82 on Thursday. The company’s 50-day moving average price is $16.40 and its 200-day moving average price is $15.68. Entrada Therapeutics has a twelve month low of $10.75 and a twelve month high of $19.95. The company has a market cap of $741.66 million, a P/E ratio of 12.47 and a beta of -0.26.

Institutional Investors Weigh In On Entrada Therapeutics

Several institutional investors have recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Entrada Therapeutics by 132.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 138,605 shares of the company’s stock valued at $2,215,000 after purchasing an additional 78,953 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Entrada Therapeutics in the second quarter worth $636,000. Los Angeles Capital Management LLC acquired a new stake in shares of Entrada Therapeutics in the third quarter valued at about $542,000. BayBridge Capital Group LLC acquired a new stake in shares of Entrada Therapeutics during the 3rd quarter valued at approximately $464,000. Finally, American Century Companies Inc. grew its stake in Entrada Therapeutics by 5.1% in the 2nd quarter. American Century Companies Inc. now owns 384,973 shares of the company’s stock valued at $5,486,000 after acquiring an additional 18,625 shares during the last quarter. 86.39% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Entrada Therapeutics news, COO Nathan J. Dowden sold 1,904 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.07, for a total transaction of $28,693.28. Following the transaction, the chief operating officer now directly owns 125,996 shares in the company, valued at $1,898,759.72. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Natarajan Sethuraman sold 2,642 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.09, for a total transaction of $39,867.78. Following the completion of the transaction, the insider now directly owns 183,816 shares of the company’s stock, valued at $2,773,783.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Nathan J. Dowden sold 1,904 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $15.07, for a total value of $28,693.28. Following the transaction, the chief operating officer now directly owns 125,996 shares of the company’s stock, valued at approximately $1,898,759.72. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,187 shares of company stock valued at $155,947. Company insiders own 7.59% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.